Stifel Nicolaus Sticks to Its Buy Rating for Repligen (RGEN)
at www.tipranks.com (Wed, 25-Feb 10:56 AM)
Repligen: Solid Execution and Credible Growth Outlook, But Upside Limited at Current Valuation
at www.tipranks.com (Wed, 25-Feb 8:25 AM)
Barclays Keeps Their Buy Rating on Repligen (RGEN)
at www.tipranks.com (Wed, 25-Feb 4:58 AM)
KeyBanc Remains a Buy on Repligen (RGEN)
at www.tipranks.com (Wed, 25-Feb 4:56 AM)
Repligen Signals Confident Growth Path In 2026 Outlook
at www.tipranks.com (Tue, 24-Feb 7:22 PM)
at www.tipranks.com (Tue, 24-Feb 4:05 PM)
Repligen outlines $810M–$840M 2026 revenue target while expanding analytics and protein franchises
at seekingalpha.com (Tue, 24-Feb 2:28 PM)
Analysts Are Bullish on Top Healthcare Stocks: Repligen (RGEN), Myriad Genetics (MYGN)
at www.tipranks.com (Tue, 24-Feb 9:31 AM)
Analysts’ Top Healthcare Picks: Harmony Biosciences Holdings (HRMY), Repligen (RGEN)
at www.tipranks.com (Tue, 24-Feb 9:01 AM)
Repligen beats top-line and bottom-line estimates; introduces FY26 outlook
at seekingalpha.com (Tue, 24-Feb 7:39 AM)
Here are the major earnings before the open Tuesday
at seekingalpha.com (Mon, 23-Feb 6:00 PM)
Repligen Q4 2025 Earnings Preview
at seekingalpha.com (Mon, 23-Feb 10:08 AM)
